lav-blot ii Search Results


hiv 2 based western blot wb test  (Valiant Co Ltd)
95
Valiant Co Ltd hiv 2 based western blot wb test
Hiv 2 Based Western Blot Wb Test, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/Protein+S/pmc04016034-193-12-17
Average 95 stars, based on 1 article reviews
hiv 2 based western blot wb test - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
hiv 2 blot version 1 2  (Valiant Co Ltd)
96
Valiant Co Ltd hiv 2 blot version 1 2
Hiv 2 Blot Version 1 2, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/HIV-2+Blot+1%2E2/pmc03106263-79-21-25
Average 96 stars, based on 1 article reviews
hiv 2 blot version 1 2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
gs hiv 1 hiv 2 plus o eia  (Bio-Rad)
93
Bio-Rad gs hiv 1 hiv 2 plus o eia
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Gs Hiv 1 Hiv 2 Plus O Eia, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/GS+HIV-1%2FHIV-2+PLUS+O+EIA/pmc07122649-55-0-14
Average 93 stars, based on 1 article reviews
gs hiv 1 hiv 2 plus o eia - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
hiv 2 western blot  (Valiant Co Ltd)
94
Valiant Co Ltd hiv 2 western blot
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Hiv 2 Western Blot, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/HIV+Blot+2%2E2/pm32305880-37-75-79
Average 94 stars, based on 1 article reviews
hiv 2 western blot - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti hiv antibodies  (Fujirebio Inc)
95
Fujirebio Inc anti hiv antibodies
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Anti Hiv Antibodies, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/INNO-LIA+HIV+I%2FII+Score/pmc08555813-426-7-18
Average 95 stars, based on 1 article reviews
anti hiv antibodies - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
ii confirmation kits  (Bio-Rad)
96
Bio-Rad ii confirmation kits
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Ii Confirmation Kits, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/Bio-Rad+Protein+Assay+Kit+II/pmc04003148-108-9-17
Average 96 stars, based on 1 article reviews
ii confirmation kits - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
gs hiv 2 eia  (Bio-Rad)
94
Bio-Rad gs hiv 2 eia
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Gs Hiv 2 Eia, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/GS+HIV-2+EIA/pmc04719082-44-8-11
Average 94 stars, based on 1 article reviews
gs hiv 2 eia - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
eia screening tests  (Bio-Rad)
93
Bio-Rad eia screening tests
Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="250" height="auto" />
Eia Screening Tests, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/Bio-Rad+ANA+Screening+Test/10__1309_slash_lmm3x37nswucmvrs-30-42-51
Average 93 stars, based on 1 article reviews
eia screening tests - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
hiv uni-form ii plus o  (bioMerieux gmbh)
90
bioMerieux gmbh hiv uni-form ii plus o
Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in <t> HIV‐positive </t> people
Hiv Uni Form Ii Plus O, supplied by bioMerieux gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/hiv+1+western+blot/pmc06513489-208-14-25
Average 90 stars, based on 1 article reviews
hiv uni-form ii plus o - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
lav blot ii  (Bio-Rad)
93
Bio-Rad lav blot ii
Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in <t> HIV‐positive </t> people
Lav Blot Ii, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/Liquichek+Diabetes+Control/pm26315319-41-15-11
Average 93 stars, based on 1 article reviews
lav blot ii - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
hiv-2 enzyme immunoassay  (DuPont de Nemours)
90
DuPont de Nemours hiv-2 enzyme immunoassay
Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in <t> HIV‐positive </t> people
Hiv 2 Enzyme Immunoassay, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/hiv+2+enzyme+immunoassay/pm08729629-58-99-80
Average 90 stars, based on 1 article reviews
hiv-2 enzyme immunoassay - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
western blot hiv blot 1-2  (Genelabs Technologies Inc)
90
Genelabs Technologies Inc western blot hiv blot 1-2
Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in <t> HIV‐positive </t> people
Western Blot Hiv Blot 1 2, supplied by Genelabs Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lav-blot+ii/htlv+blot+2+4/pm09233463-61-37-44
Average 90 stars, based on 1 article reviews
western blot hiv blot 1-2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ <xref ref-type= 48 ])" width="100%" height="100%">

Journal: Advanced Techniques in Diagnostic Microbiology

Article Title: Molecular Techniques for Blood and Blood Product Screening

doi: 10.1007/978-1-4614-3970-7_28

Figure Lengend Snippet: Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ 48 ])

Article Snippet: GS HIV-1/HIV-2 Plus O EIA , EIA , Serum/Plasma/Cadaveric serum , Donor screen , Bio-Rad Laboratories, Redmond, WA; US License 1109 , 8/5/2003.

Techniques: HBsAg Assay, Enzyme-linked Immunosorbent Assay, Diagnostic Assay, Clinical Proteomics, Virus, Stripping Membranes, Western Blot, Viral-load Assay, DNA Sequencing, Amplification, Biomarker Discovery, Infection, Reverse Transcription, Polymerase Chain Reaction, Quantitation Assay, T. Cruzi Assay

Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in HIV‐positive people

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet: Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in HIV‐positive people

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Comparison, Sampling

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet:

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Infection, Virus

<xref ref-type= Chetchotisakd 2004 " width="100%" height="100%">

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet: Chetchotisakd 2004

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Infection, Sequencing, Selection

<xref ref-type= Hakim 2017 " width="100%" height="100%">

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet: Hakim 2017

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Transmission Assay, Sequencing, Selection, Generated, Biomarker Discovery

<xref ref-type= Parkes‐Ratanshi 2011 " width="100%" height="100%">

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet: Parkes‐Ratanshi 2011

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Infection, Western Blot, Sequencing, Selection

<xref ref-type= Schuman 1997 " width="100%" height="100%">

Journal: The Cochrane Database of Systematic Reviews

Article Title: Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people

doi: 10.1002/14651858.CD004773.pub3

Figure Lengend Snippet: Schuman 1997

Article Snippet: Participants , Inclusion criteria : ART‐naïve adults (> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/μL (FACSCount Becton Dickinson, USA) Exclusion criteria : serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of normal (ULN), and moribund patients. Number randomized : 1519 Descriptive baseline data: Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8) Sex [% male]: fluconazole 38%; placebo 33% CD4 count [median (IQR) cells/mm3]: fluconazole 110 (45 to 160); placebo 112 (48 to 157) ART regimen provided: triple Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 days CrAg status: CrAG‐positive:1519/1519 % on ART: fluconazole 84%; placebo 87% Duration of follow‐up [median (range) weeks]: fluconazole 59 (27 to 124); placebo 60 (28 to 123) Dropouts during study period: fluconazole (4%); placebo (2.5%) , .

Techniques: Western Blot, Enzyme-linked Immunosorbent Assay, Sequencing, Selection, Blocking Assay